1001646-85-0

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE is used as a reagent in chemical synthesis for the production of new drug candidates. Its unique structure and reactivity contribute to the development of innovative pharmaceuticals, enhancing the range of available treatments.
Used in Organic Chemistry Research:
In the realm of organic chemistry, (R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE serves as a building block for the construction of more complex molecules. Its versatility and functional groups make it an essential tool for creating novel compounds with potential applications in various fields.
Used in Drug Development:
(R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE is utilized in drug development processes to create new molecular entities with therapeutic potential. Its role in the synthesis of complex molecules aids in the discovery and optimization of drug candidates, ultimately contributing to advancements in medicine.

Upstream product

• 890849-78-2 C₂₃H₃₂N₂O₆ 
• 871675-56-8 4-(3-benzyloxycarbonylamino-3-methoxycarbonyl-allyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTlVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

Compounds and Compositions as Channel Activating Protease Inhibitors

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.